{"entity":{"id":"nct06930755","kind":"trial","name":"Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06930755 as recruiting, last updated 2026-05-28. Enrolment is 24 planned participants, an estimate. Interventions: NMS-03305293, Topotecan. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06930755","url":"https://clinicaltrials.gov/study/NCT06930755"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["nms-03305293"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06930755","phase":"1","setting":"Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer","sponsor":"Nerviano Medical Sciences","started":"2026-05-13","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06930755/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"nms-03305293","kind":"drug","name":"NMS-03305293","route":"/drugs/nms-03305293/"}]}}